Tag Archives: NEPTUNUS-1

Novartis Phase III Trials Show Ianalumab Significantly Improves Outcomes in Sjögren’s Disease

(IN BRIEF) Novartis has reported landmark Phase III results showing that ianalumab significantly reduced disease activity in patients with Sjögren’s disease, meeting primary endpoints in both the NEPTUNUS-1 and NEPTUNUS-2 trials. The treatment, which combines B-cell depletion and BAFF-R inhibition, … Read the full press release